An interventional study of Lactated Ringer's and Lactated Ringers Stroke Volume Based Dosing in Acute Pancreatitis (AP), sponsored by University of Southern California. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by University of Southern California · Not applicable, Interventional, and Treatment
The SUSTAIN Trial is a randomized control trial that allows for the control of aggressive hydration that is currently used in an inpatient setting, which can result is fluid overload in certain patients. With the impression that changes in stroke volume in individual patient will further improve the outcome.
The proposed SUSTAIN Trial Study (Stroke volUme-baSed fluid resuscitation), a multi-center randomized controlled trial which will address these knowledge gaps in acute pancreatitis. Recently demonstration from the WATERFALL (Early Weight-Based Aggressive vs. ModeraTE Goal-DiRected Fluid ResuscitAtion) randomized controlled trial that aggressive hydration increased the risk of fluid overload without improving the clinical course of AP compared with a moderate hydration strategy. With further suggestions, rather than a generic body weight-based approach, tailoring fluid requirements to changes in stoke volume in individual patients will further improve outcomes.
557 studies on the registry are indexed under Pancreatitis; 164 are open to participants now.
This study's planned enrollment of 80 is below the median of 100 across 349 interventional studies indexed under Pancreatitis.
Browse Pancreatitis studies →University of Southern California is the lead sponsor of 791 studies on the registry; 136 are open to participants now.
Of its 70 completed or terminated interventional studies of FDA-regulated products, 32 (46%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
We suggest that changes in stroke volume on individual patients can further improve outcomes with fluid resuscitation and prevent fluid overload in the individuals with acute pancreatitis.
Other: Lactated Ringers Stroke Volume Based Dosing
This arm is based on a past fluid resuscitation study, WATERFALL Study, where there was moderate fluid resuscitation in the setting of treatment for acute pancreatitis.
Other: Lactated Ringer's
lactated ringer's in intervention is dosed based on changes in stroke volume versus a weight based strategy
Lactated Ringers Rate is based on changes in stroke volume
SIRS Values at the 48 hours after enrollement
The primary endpoint for this study will be the presence of SIRS at 48 hours from enrollment defined as \>2 SIRS criteria (HR \>90, RR \>20, temperature \>38C or \<36C, and WBC \>12,000 or \<4,000 cells/mm3). SIRS is a marker of disease severity and also may be converted to a SIRS score (number of criterion).
Time frame: 48 hours
Secondary Clinical Endpoints
\- Participants who have a \>=2 SIRS score
Time frame: Beginning of randomization to 48 hours and between endpoints.
Modified pancreatitis activity scoring system (mPASS) score.
Time frame: From enrollment until 48 hours following enrollment.
Complications that arise during the inpatient setting
Local complications, incidence and interventions, Organ failure, incidence and interventions (RAC definitions)
Time frame: From enrollment until 30 days after enrollment.
Dutch Composite Endpoint
Including death and major morbidity
Time frame: Day 30
Participant's Condition during their length of stay (LOS)
The amount of days alive and wellbeing of the participant, including length of stay (LOS) and days in/out of the Intensive Care Unit (ICU)
Time frame: From enrollment to 30 days after enrollment.
C Reactive protein
Will be collected at randomization with the respective units: mg/dL
Time frame: Randomization to 48 hours and between timepoints
IL-6
Will be collected at randomization with the respective units: pg/dL
Time frame: Randomization to 48 hours and between timepoints
MCP-1
Will be collected with the respective units: pg/dL
Time frame: Randomization to 48 hours and between timepoints
Resistin
Inflammatory Response. Will be collected with the respective units: ng/dL
Time frame: Randomization to 48 hours and between timepoints
Angiopoietin-2
Endothelial Function. Will be collected with the respective units: pg/dL
Time frame: Randomization to 48 hours and between timepoints
IL-8
Will be collected with the respective units: pg/dL
Time frame: Randomization to 48 hours and between timepoints
Lactate
Global tissue perfusion. Will be collected with the respective units: mg/dL
Time frame: Randomization to 48 hours and between timepoints
Not enrolling at this site.
Plan to share: Undecided — De-identified data will be made publicly available at the conclusion of the study and following publication of the primary manuscript.
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.
Of 91 non-industry interventional studies with no phase under Pancreatitis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 24 months is below that.
Counting every sponsor, half of 94 studies reached it within 32 months; a quarter within 23 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Southern California →